Inflammatory breast cancer: New factors contribute to disease etiology: A review

Journal of Advanced Research

Volumn 5, Issue 5, 2014, Pages 525-536

  Mohamed, Mona M ^a   Al Raawi, Diaa ^b   Sabet, Salwa F ^a   El Shinawi, Mohamed ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b SANA A UNIVERSITY   (Yemen)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Cytokines; Inflammatory breast cancer; Proteases; Viral infection

Indexed keywords

EID: 84908021479     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2013.06.004     Document Type: Review

References (138)

1. Lee B.T., Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obste 1924, 39:580-595.
2. Taylor G., Meltzer A. "Inflammatory carcinoma" of the breast. Am J Cancer 1938, 33:33-49.
3. Robertson F.M., Bondy M., Yang W., Yamauchi H., Wiggins S., Kamrudin S., et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010, 60(6):351-375.
4. Hance K.W., Anderson W.F., Devesa S.S., Young H.A., Levine P.H. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005, 97(13):966-975.
5. Schairer C., Brown L.M., Mai P.L. Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Res Treat 2011, 129(1):117-124.
6. Labidi S.I., Mrad K., Mezlini A., Ouarda M.A., Combes J.D., Ben Abdallah M. Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 2008, 19(3):473-480.
7. Dawood S., Cristofanilli M. Inflammatory breast cancer: what progress have we made?. Oncology (Williston Park) 2011, 25(3):264-270. 273.
8. Schairer C., Soliman A.S., Omar S., Khaled H., Eissa S., Ayed F.B., et al. Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med 2013, 2(2):178-184.
9. Mourali N., Muenz L.R., Tabbane F., Belhassen S., Bahi J., Levine P.H. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer 1980, 46(12):2741-2746.
10. Costa J., Webber B.L., Levine P.H., Muenz L., O'Conor G.T., Tabbane F., et al. Histopathological features of rapidly progressing breast carcinoma in Tunisia: a study of 94 cases. Int J Cancer 1982, 30(1):35-37.
11. Dawood S., Merajver S.D., Viens P., Vermeulen P.B., Swain S.M., Buchholz T.A., et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2010, 22(3):515-523.
12. Chang S., Parker S.L., Pham T., Buzdar A.U., Hursting S.D. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998, 82(12):2366-2372.
13. Cristofanilli M., Buzdar A.U., Hortobagyi G.N. Update on the management of inflammatory breast cancer. Oncologist 2003, 8(2):141-148.
14. Lerebours F., Bieche I., Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 2005, 7(2):52-58.
15. Walshe J.M., Swain S.M. Clinical aspects of inflammatory breast cancer. Breast Dis 2005, 22:35-44.
16. Yamauchi H., Woodward W.A., Valero V., Alvarez R.H., Lucci A., Buchholz T.A., et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist 2012, 17(7):891-899.
17. Van Laere S.J., Ueno N.T., Finetti P., Vermeulen P.B., Lucci A., Robertson F.M., et al. Uncovering the molecular secrets of Inflammatory Breast Cancer biology: an integrated analysis of three distinct Affymetrix gene expression data sets. Clin Cancer Res 2013, 19(17):4685-4696.
18. Delarue J.C., May-Levin F., Mouriesse H., Contesso G., Sancho-Garnier H. Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer 1981, 44(6):911-916.
19. Jaiyesimi I.A., Buzdar A.U., Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992, 10(6):1014-1024.
20. Palangie T., Mosseri V., Mihura J., Campana F., Beuzeboc P., Dorval T., et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994, 30A(7):921-927.
21. Zell J.A., Tsang W.Y., Taylor T.H., Mehta R.S., Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009, 11(1):R9.
22. van Golen K.L., Davies S., Wu Z.F., Wang Y., Bucana C.D., Root H., et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999, 5(9):2511-2519.
23. Kleer C.G., Zhang Y., Pan Q., van Golen K.L., Wu Z.F., Livant D., et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002, 21(20):3172-3180.
24. Gong Y. Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype. Semin Oncol 2008, 35(1):33-40.
25. Kleer C.G., van Golen K.L., Braun T., Merajver S.D. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001, 14(5):458-464.
26. Bonnier P., Charpin C., Lejeune C., Romain S., Tubiana N., Beedassy B., et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?. Int J Cancer 1995, 62(4):382-385.
27. Kowalski P.J., Rubin M.A., Kleer C.G. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003, 5(6):R217-R222.
28. Kleer C.G., Zhang Y., Pan Q., Gallagher G., Wu M., Wu Z.F., et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004, 6(2). R110-5.
29. van Golen K.L., Bao L., DiVito M.M., Wu Z., Prendergast G.C., Merajver S.D. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 2002, 1(8):575-583.
30. van Golen K.L., Bao L.W., Pan Q., Miller F.R., Wu Z.F., Merajver S.D. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metast 2002, 19(4):301-311.
31. van Golen K.L., Wu Z.F., Qiao X.T., Bao L., Merajver S.D. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000, 2(5):418-425.
32. van Golen K.L., Wu Z.F., Qiao X.T., Bao L.W., Merajver S.D. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000, 60(20):5832-5838.
33. Van den Eynden G.G., Van der Auwera I., Van Laere S., Colpaert C.G., van Dam P., Merajver S., et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 2004, 85(1):13-22.
34. Kleer C.G., van Golen K.L., Zhang Y., Wu Z.F., Rubin M.A., Merajver S.D. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002, 160(2):579-584.
35. Kleer C.G., Griffith K.A., Sabel M.S., Gallagher G., van Golen K.L., Wu Z.F., et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 2005, 93(2):101-110.
36. Wu M., Wu Z.F., Kumar-Sinha C., Chinnaiyan A., Merajver S.D. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 2004, 84(1):3-12.
37. Lerebours F., Cizeron-Clairac G., Susini A., Vacher S., Mouret-Fourme E., Belichard C., et al. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer 2013, 133(7):1614-1623.
38. Tsoi D.T., Rowsell C., McGregor C., Kelly C.M., Verma S., Pritchard K.I. Disseminated tumor embolism from breast cancer leading to multiorgan failure. J Clin Oncol 2010, 28(12). e180-3.
39. Morales J., Alpaugh M.L. Gain in cellular organization of inflammatory breast cancer: a 3D in vitro model that mimics the in vivo metastasis. BMC Cancer 2009, 9:462.
40. Mahooti S., Porter K., Alpaugh M.L., Ye Y., Xiao Y., Jones S., et al. Breast carcinomatous tumoral emboli can result from encircling lymphovasculogenesis rather than lymphovascular invasion. Oncotarget 2010, 1(2):131-147.
41. Xiao Y., Ye Y., Yearsley K., Jones S., Barsky S.H. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol 2008, 173(2):561-574.
42. Mohamed M.M. Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway. Cell Commun Signal 2012, 10(1):3.
43. Lehman H.L., Dashner E.J., Lucey M., Vermeulen P., Dirix L., Van Laere S., et al. Modeling and characterization of inflammatory breast cancer emboli grown in vitro. Int J Cancer 2012.
44. Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008, 84(3):623-630.
45. Mukhtar R.A., Nseyo O., Campbell M.J., Esserman L.J. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 2011, 11(1):91-100.
46. Aaltomaa S., Lipponen P., Eskelinen M., Kosma V.M., Marin S., Alhava E., et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992, 28A(4-5):859-864.
47. Georgiannos S.N., Renaut A., Goode A.W., Sheaff M. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 2003, 134(5):827-834.
48. Pollard J.W. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9(4):259-270.
49. Ojalvo L.S., King W., Cox D., Pollard J.W. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol 2009, 174(3):1048-1064.
50. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8(12):958-969.
51. Lewis C.E., Leek R., Harris A., McGee J.O. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 1995, 57(5):747-751.
52. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56(20):4625-4629.
53. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124(2):263-266.
54. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metast Rev 2006, 25(3):315-322.
55. Hagemann T., Wilson J., Kulbe H., Li N.F., Leinster D.A., Charles K., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005, 175(2):1197-1205.
56. Gonzalez L.O., Pidal I., Junquera S., Corte M.D., Vazquez J., Rodriguez J.C., et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 2007, 97(7):957-963.
57. O'Sullivan C., Lewis C.E., Harris A.L., McGee J.O. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993, 342(8864):148-149.
58. Van Laere S., Van der Auwera I., Van den Eynden G.G., Fox S.B., Bianchi F., Harris A.L., et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005, 93(3):237-246.
59. Compton T., Kurt-Jones E.A., Boehme K.W., Belko J., Latz E., Golenbock D.T., et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003, 77(8):4588-4596.
60. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66(2):605-612.
61. Mohamed M.M., Cavallo-Medved D., Sloane B.F. Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer. Biol Chem 2008, 389(8):1117-1121.
62. Nouh M.A., Mohamed M.M., El-Shinawi M., Shaalan M.A., Cavallo-Medved D., Khaled H.M., et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med 2011, 9:1.
63. Al-Raawi D., Abu-El-Zahab H., El-Shinawi M., Mohamed M.M. Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer. Int J Clin Exp Med 2011, 4(4):265-275.
64. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006, 6(10):764-775.
65. Lee M., Fridman R., Mobashery S. Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 2004, 33(7):401-409.
66. Opdenakker G., Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 1992, 4(4):251-258.
67. Place A.E., Jin Huh S., Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011, 13(6):227.
68. Sameni M., Anbalagan A., Olive M.B., Moin K., Mattingly R.R., Sloane B.F. MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression. J Vis Exp 2012, (60).
69. Rothberg J.M., Sameni M., Moin K., Sloane B.F. Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. Biochim Biophys Acta 2012, 1824(1):123-132.
70. Van den Eynden G.G., Van Laere S.J., Van der Auwera I., Merajver S.D., Van Marck E.A., van Dam P., et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006, 95(3):219-228.
71. Cavallo-Medved D., Mai J., Dosescu J., Sameni M., Sloane B.F. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005, 118(Pt 7):1493-1503.
72. Cavallo-Medved D., Rudy D., Blum G., Bogyo M., Caglic D., Sloane B.F. Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res 2009, 315(7):1234-1246.
73. Cavallo-Medved D., Sloane B.F. Cell-surface cathepsin B: understanding its functional significance. Curr Top Dev Biol 2003, 54:313-341.
74. Ren W.P., Sloane B.F. Cathepsins D and B in breast cancer. Cancer Treat Res 1996, 83:325-352.
75. Kobayashi H., Moniwa N., Sugimura M., Shinohara H., Ohi H., Terao T. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1993, 1178(1):55-62.
76. Victor B.C., Anbalagan A., Mohamed M.M., Sloane B.F., Cavallo-Medved D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res 2011, 13(6):R115.
77. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
78. Vihinen P., Ala-aho R., Kahari V.M. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005, 5(3):203-220.
79. Kohrmann A., Kammerer U., Kapp M., Dietl J., Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009, 9:188.
80. Patel S., Sumitra G., Koner B.C., Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem 2011, 44(10-11):869-872.
81. Ray J.M., Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994, 7(11):2062-2072.
82. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2(4):252-257.
83. Noel A., Gutierrez-Fernandez A., Sounni N.E., Behrendt N., Maquoi E., Lund I.K., et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol 2012, 3:140.
84. Noh S., Jung J.J., Jung M., Kim T.S., Park C.H., Lim S.J., et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology 2011, 58(112):2015-2019.
85. Damodharan U., Ganesan R., Radhakrishnan U.C. Expression of MMP2 and MMP9 (gelatinases A and B) in human colon cancer cells. Appl Biochem Biotechnol 2011, 165(5-6):1245-1252.
86. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011, 278(1):16-27.
87. Sounni N.E., Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005, 87(3-4):329-342.
88. Noel A., Maillard C., Rocks N., Jost M., Chabottaux V., Sounni N.E., et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004, 57(6):577-584.
89. Figueira R.C., Gomes L.R., Neto J.S., Silva F.C., Silva I.D., Sogayar M.C. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009, 9:20.
90. Jiang W.G., Davies G., Martin T.A., Parr C., Watkins G., Mason M.D., et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 2006, 17(4):583-590.
91. Kousidou O.C., Roussidis A.E., Theocharis A.D., Karamanos N.K. Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res 2004, 24(6):4025-4030.
92. de Andres P.J., Illera J.C., Caceres S., Diez L., Perez-Alenza M.D., Pena L. Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer. Vet Immunol Immunopathol 2012.
93. Debeb B.G., Cohen E.N., Boley K., Freiter E.M., Li L., Robertson F.M., et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat 2012, 134(2):495-510.
94. Bieche I., Lerebours F., Tozlu S., Espie M., Marty M., Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004, 10(20):6789-6795.
95. Drygin D., Ho C.B., Omori M., Bliesath J., Proffitt C., Rice R., et al. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophys Res Commun 2011, 415(1):163-167.
96. Kurebayashi J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000, 7(2):124-129.
97. Knupfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007, 102(2):129-135.
98. Arihiro K., Oda H., Kaneko M., Inai K. Cytokines facilitate chemotactic motility of breast carcinoma cells. Breast Cancer 2000, 7(3):221-230.
99. Lerebours F., Vacher S., Andrieu C., Espie M., Marty M., Lidereau R., et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008, 8:41.
100. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69(4):1302-1313.
101. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71(2):614-624.
102. Giampieri S., Manning C., Hooper S., Jones L., Hill C.S., Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009, 11(11):1287-1296.
103. Giampieri S., Pinner S., Sahai E. Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis. Cancer Res 2010, 70(9):3435-3439.
104. Glenn W.K., Heng B., Delprado W., Iacopetta B., Whitaker N.J., Lawson J.S. Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS ONE 2012, 7(11):e48788.
105. Wang Y., Holland J.F., Bleiweiss I.J., Melana S., Liu X., Pelisson I., et al. Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res 1995, 55(22):5173-5179.
106. Liu B., Wang Y., Melana S.M., Pelisson I., Najfeld V., Holland J.F., et al. Identification of a proviral structure in human breast cancer. Cancer Res 2001, 61(4):1754-1759.
107. Fawzy S., Sallam M., Awad N.M. Detection of Epstein-Barr virus in breast carcinoma in Egyptian women. Clin Biochem 2008, 41(7-8):486-492.
108. Harkins L.E., Matlaf L.A., Soroceanu L., Klemm K., Britt W.J., Wang W., et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 2010, 1(1):8.
109. Pogo B.G., Holland JF.., Levine P.H. Human mammary tumor virus in inflammatory breast cancer. Cancer 2010, 116(11 Suppl):2741-2744.
110. Soliman A.S., Banerjee M., Lo A.C., Ismail K., Hablas A., Seifeldin I.A., et al. High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt. Egypt. Breast J 2009, 15(4):432-434.
111. Soliman A.S., Lo A.C., Banerjee M., El-Ghawalby N., Khaled H.M., Bayoumi S., et al. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution. Carcinogenesis 2007, 28(8):1794-1799.
112. Soliman A.S., Vulimiri S.V., Kleiner H.E., Shen J., Eissa S., Morad M., et al. High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt. Int J Environ Health Res 2004, 14(2):121-134.
113. Soliman A.S., Wang X., Stanley J.D., El-Ghawalby N., Bondy M.L., Ezzat F., et al. Geographical clustering of pancreatic cancers in the Northeast Nile Delta region of Egypt. Arch Environ Contam Toxicol 2006, 51(1):142-148.
114. Fiorentini S., Luganini A., Dell'Oste V., Lorusso B., Cervi E., Caccuri F., et al. Human cytomegalovirus productively infects lymphatic endothelial cells and induces a secretome that promotes angiogenesis and lymphangiogenesis through interleukin-6 and granulocyte-macrophage colony-stimulating factor. J Gen Virol 2011, 92(Pt 3):650-660.
115. Juckem L.K., Boehme K.W., Feire A.L., Compton T. Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells. J Immunol 2008, 180(7):4965-4977.
116. Michaelis M., Doerr H.W., Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 2009, 11(1):1-9.
117. Fagundes C.P., Glaser R., Alfano C.M., Bennett J.M., Povoski S.P., Lipari A.M., et al. Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain Behav Immun 2011.
118. Breathnach O., Donnellan P., Collins D., McNicholas W., Crown J. Cytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: case report and review of the literature. Ann Oncol 1999, 10(4):461-465.
119. Cheeran M.C., Hu S., Yager S.L., Gekker G., Peterson P.K., Lokensgard J.R. Cytomegalovirus induces cytokine and chemokine production differentially in microglia and astrocytes: antiviral implications. J Neurovirol 2001, 7(2):135-147.
120. Roberts E.T., Haan M.N., Dowd J.B., Aiello A.E. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol 2010, 172(4):363-371.
121. El-Shinawi M., Mohamed H.T., El-Ghonaimy E.A., Tantawy M., Younis A., Schneider R.J., et al. Human cytomegalovirus infection enhances NF-kappaB/p65 signaling in inflammatory breast cancer patients. PLoS ONE 2013, 8(2):e55755.
122. Cristofanilli M., Gonzalez-Angulo A.M., Buzdar A.U., Kau S.-W., Frye D.K., Hortobagyi G.N. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin. Breast Cancer 2004, 4(6):415-419.
123. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375(9712):377-384.
124. Hurley J., Doliny P., Reis I., Silva O., Gomez-Fernandez C., Velez P., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2006, 24(12):1831-1838.
125. Curcio L.D., Rupp E., Williams W.L., Chu D.Z., Clarke K., Odom-Maryon T., et al. Beyond palliative mastectomy in inflammatory breast cancer - a reassessment of margin status. Ann Surg Oncol 1999, 6(3):249-254.
126. Bristol I.J., Woodward W.A., Strom E.A., Cristofanilli M., Domain D., Singletary S.E., et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2008, 72(2):474-484.
127. Hillyer R.L., Sirinvasin P., Joglekar M., Sikes R.A., van Golen K.L., Nohe A. Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines. Clin Exp Metast 2012, 29(8):971-979.
128. Kavandi L., Collier M.A., Nguyen H., Syed V. Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell Biochem 2012, 113(10):3143-3152.
129. Miller L.J., Kurtzman S.H., Anderson K., Wang Y., Stankus M., Renna M., et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 2000, 18(4):293-302.
130. Pantschenko A.G., Pushkar I., Miller L.J., Wang Y.P., Anderson K., Peled Z., et al. In vitro demonstration of breast cancer tumor cell sub-populations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 2003, 10(4):1011-1017.
131. Angelo L.S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007, 13(10):2825-2830.
132. Lin Y., Huang R., Chen L., Li S., Shi Q., Jordan C., et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 2004, 109(4):507-515.
133. Papiernik M., Do Carmo Leite-de-Moraes M., Pontoux C., Joret A.M., Rocha B., Penit C. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J Immunol 1997, 158(10):4642-4653.
134. Li C.-W., Xia W., Huo L., Lim S.-O., Wu Y., Hsu J.L., et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res 2012, 72(5):1290-1300.
135. Wu S.-T., Sun G.-H., Hsu C.-Y., Huang C.-S., Wu Y.-H., Wang H.-H., et al. Tumor necrosis factor-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a nuclear factor kappa B-independent mechanism. Exp Biol Med 2011, 236(9):1022-1029.
136. Storci G., Sansone P., Mari S., D'Uva G., Tavolari S., Guarnieri T., et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 2010, 225(3):682-691.
137. Qian B.-Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475(7355):222-225.
138. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256(2):137-165.